Momenta Pharmaceuticals Announces Top-Line Part A Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer

CAMBRIDGE, Mass., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA ), a biotechnology company specializing in the characterization and engineering of complex drugs, announced top-line results from the dose-escalation component (Part A) of the Phase 1/2 trial evaluating necuparanib in combination with Abraxane ® (ABX; nab -paclitaxel) and gemcitabine (GEM) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243). A dose was established to take forward into Part B (Phase 2) of the trial, which is a randomized, controlled, proof-of-concept study to evaluate the antitumor activity of necuparanib in combination with ABX and GEM, compared with ABX and GEM alone.

Part A is a Phase 1 study of escalating daily necuparanib doses in combination with 125 mg/m 2 ABX and 1000 mg/m 2 GEM (Days 1, 8, and 15 of each 28-day cycle) in patients with metastatic pancreatic cancer. The necuparanib starting dose was 0.5 mg/kg, which was increased via a modified 3+3 design until a maximum tolerated dose was determined. ABX was added to the treatment regimen starting with Cohort 3 following release of the Phase 3 ABX + GEM data last year. Thirty-seven patients (12 patients in the first two cohorts and 25 patients in the five subsequent cohorts) received necuparanib as of data cutoff and were included in the analyses. Top-line results included:

  • The most common (≥30% of patients) AEs included anemia, fatigue, nausea, diarrhea, and vomiting – comparable to what has been observed for ABX and GEM alone.
  • Twelve patients were treated with the combination regimen of necuparanib, ABX, and GEM and have completed the first 28-day cycle as of data cutoff. All 12 of these patients also had at least one follow up CT scan and were considered evaluable for radiographic response. Seven (58%) achieved a RECIST partial response (PR) and an additional 4 (33%) achieved stable disease (SD). Disease Control (the # of patients with Complete Response + PR + SD / total # of evaluable patients) was achieved in 11/12 (92%).
  • All twelve evaluable patients also had >20%; and 11/12 had >50% decreases from baseline in CA19.9 levels (a predictive biomarker for long-term outcome and treatment response in pancreatic cancer).

Data have been submitted to the 2015 Gastrointestinal Cancers Symposium for consideration.

"Necuparanib continues to be a promising compound with several potential and relevant mechanisms of action in pancreatic cancer, a field with limited treatment options. Based on the favorable tolerability and encouraging early signals of potential efficacy observed to date, I look forward to further exploring necuparanib in the Part B portion of the Phase 1/2 study," said David Ryan, M.D., Chief of Hematology and Oncology and Clinical Director of the Tucker Gosnell Center for Gastrointestinal Cancers at Massachusetts General Hospital, and Lead Investigator in the trial.

"We are pleased to have achieved a dose of necuparanib in Part A that is significantly higher than the doses of low molecular weight heparins historically tested in studies conducted to evaluate the effect of heparins on survival in patients with cancer," said Jim Roach, M.D., Chief Medical Officer of Momenta Pharmaceuticals. "We are eager to begin dosing patients in the next few weeks in the Part B portion of the study. Furthermore, we look forward to presenting and publishing data from the Part A study regarding safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy over the next several months."

About Necuparanib
Necuparanib (formerly M402) is a novel oncology drug candidate engineered to have a broad range of effects on tumor cells. The use of heparins to treat venous thrombosis in cancer patients has generated numerous reports of antitumor activity; however, the dose of these products has been limited by their anticoagulant activity. Leveraging its experience in deciphering the structure-function relationships of complex therapeutics, Momenta engineered necuparanib from unfractionated heparin to have significantly reduced anticoagulant activity while preserving relevant antitumor properties associated with heparins. In June 2014, necuparanib received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com , which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward-Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the Company's timing for clinical development of necuparanib and publication of clinical trial results. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 Media Relations: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060 Business Development: Momenta Pharmaceuticals 1-617-491-9700

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 8

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 101

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 10

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 128

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 99

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 159

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 229

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into National HealthCare Corporation by Kaskela Law

Updated Category News Views 203

Kaskela Law LLC Announces Investigation Kaskela Law LLC has recently launched an investigation into National HealthCare Corporation (NYSE: NHC) on behalf of its shareholders. This inquiry seeks to determine if the company or its executives have violated securities laws or breached their fiduciary duties in light of recent corporate actions. Investigation Objectives The...

Continue Reading
HOPE Therapeutics Expands Its Reach in Florida’s Mental Health Care

Updated Category News Views 161

HOPE Therapeutics Welcomes Cohen & Associates to the Network In an exciting advancement, HOPE Therapeutics, Inc. has recently integrated Cohen & Associates, LLC into its expanding professional framework, aimed at revolutionizing the landscape of interventional psychiatry. This noteworthy inclusion signals a meaningful step in enhancing mental health services across...

Continue Reading
Abdullah Abdin Ready Mix Concrete's Historic Certification Milestone

Updated Category News Views 217

Abdullah Abdin Ready Mix Concrete Announces Historic Achievement Setting new standards in sustainability and innovation, Abdullah Abdin Ready-Mix Concrete has proudly achieved the prestigious Concrete Sustainability Council (CSC) certification. This recognition establishes the company as the first ready-mix concrete firm in the MENA region to receive such an influential...

Continue Reading
The Tragic Shooting of Charlie Kirk: National Outrage Ensues

Updated Category News Views 393

The Shocking Assassination of Charlie Kirk Conservative political activist Charlie Kirk was tragically shot and killed while addressing a gathering. This shocking incident has ignited a series of investigations and public responses, leading to numerous political reactions across the nation. Details Surrounding the Incident The violent act took place during Kirk's speech,...

Continue Reading
Cibus Global Ltd. Faces Market Challenges with Stock Dip

Updated Category News Views 129

Cibus Global Ltd. Faces Significant Stock Decline In recent trading sessions, Cibus Global Ltd. (CBUS) stock encountered a dramatic decline, hitting a 52-week low of $2.36. This notable drop is stark when compared to its previous high of $23.18, showing a staggering reduction of approximately 88.48% over the past year. The plummeting share price has raised alarms among...

Continue Reading